A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
NCT: NCT06388707 · RECRUITING
広告
NCT識別子NCT06388707
ステータスRECRUITING
開始日2024-09-13
完了2027-10-31
SponsorNaviFUS Corporation (INDUSTRY)
First posted
Last updated
概要
This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with drug-resistant unilateral or bilateral temporal lobe epilepsy (DR-TLE).
公式ソース
ClinicalTrials.govで見る →データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。